Anti-RUNX2 antibody [1D8] (ab115899)

Overview

• Product nameAnti-RUNX2 antibody [1D8]See all RUNX2 primary antibodies ...
• Description
  Mouse monoclonal [1D8] to RUNX2
• Tested applicationsWB, ELISA, IHC-P, ICC/IF more details
• Species reactivity
  Reacts with: Human
  
• Immunogen

  Recombinant fragment, corresponding to a region within amino acids 251-351 of Human RUNX2 (NP_004339) with a 26 kDa proprietary tag.

• Positive controlIHC-P: Human prostate and uterus tissues WB: SJCRH30 and K562 cell lysates ICC/IF: HeLa cell

Properties

• FormLiquid
• Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
• Storage bufferpH: 7.20
  Constituent: 99% PBS
• Concentration information loading...
• PurityProtein A purified
• Clonality Monoclonal
• Clone number1D8
• IsotypeIgG2b
• Light chain typekappa
• Research Areas
  • Developmental Biology
  • Organogenesis
  • Skeletal development
  • Bone

  • Stem Cells
  • Mesenchymal Stem Cells
  • Osteogenesis

  • Other

  • Epigenetics and Nuclear Signaling
  • Transcription
  • Other factors

  • Epigenetics and Nuclear Signaling
  • Transcription
  • Transcription Factors

Applications

Target

• FunctionTranscription factor involved in osteoblastic differentiation and skeletal morphogenesis. Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters (By similarity). Inhibits MYST4-dependent transcriptional activation.
• Tissue specificitySpecifically expressed in osteoblasts.
• Involvement in diseaseDefects in RUNX2 are the cause of cleidocranial dysplasia (CLCD) [MIM:119600]; also known as cleidocranial dysostosis (CCD). CLCD is an autosomal dominant skeletal disorder with high penetrance and variable expressivity. It is due to defective endochondral and intramembranous bone formation. Typical features include hypoplasia/aplasia of clavicles, patent fontanelles, wormian bones (additional cranial plates caused by abnormal ossification of the calvaria), supernumerary teeth, short stature, and other skeletal changes. In some cases defects in RUNX2 are exclusively associated with dental anomalies.
• Sequence similaritiesContains 1 Runt domain.
• DomainA proline/serine/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes and contains the phosphorylation sites.
• Post-translational
  modificationsPhosphorylated; probably by MAP kinases (MAPK) (By similarity). Isoform 3 is phosphorylated on Ser-340.
• Cellular localizationNucleus.

Target information above from: UniProt accession Q13950 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010) .

Information by UniProt
• Database links
  • Entrez Gene: 860 Human
  • Omim: 600211 Human
  • SwissProt: Q13950 Human
  • Unigene: 535845 Human

• Alternative names
  Acute myeloid leukemia 3 protein antibodyAlpha subunit 1 antibodyAML3 antibody

  CBF alpha 1 antibodyCBF-alpha-1 antibodyCBFA1 antibodyCCD antibodyCCD1 antibodyCleidocranial dysplasia 1 antibodyCore binding factor antibodyCore binding factor runt domain alpha subunit 1 antibodyCore binding factor subunit alpha 1 antibodyCore-binding factor subunit alpha-1 antibodyMGC120022 antibodyMGC120023 antibodyOncogene AML 3 antibodyOncogene AML-3 antibodyOSF 2 antibodyOSF-2 antibodyOSF2 antibodyOsteoblast specific transcription factor 2 antibodyOsteoblast-specific transcription factor 2 antibodyOTTHUMP00000016533 antibodyPEA2 alpha A antibodyPEA2-alpha A antibodyPEA2aA antibodyPEBP2 alpha A antibodyPEBP2-alpha A antibodyPEBP2A1 antibodyPEBP2A2 antibodyPEBP2aA antibodyPEBP2aA1 antibodyPolyomavirus enhancer binding protein 2 alpha A subunit antibodyPolyomavirus enhancer-binding protein 2 alpha A subunit antibodyRunt domain antibodyRunt related transcription factor 2 antibodyRunt-related transcription factor 2 antibodyRUNX2 antibodyRUNX2_HUMAN antibodySL3 3 enhancer factor 1 alpha A subunit antibodySL3-3 enhancer factor 1 alpha A subunit antibodySL3/AKV core binding factor alpha A subunit antibodySL3/AKV core-binding factor alpha A subunit antibody

  see all

Anti-RUNX2 antibody [1D8] images

• 

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-RUNX2 antibody [1D8] (ab115899)
  ab115899, at 5 µg/ml, staining RUNX2 in formalin fixed, paraffin embedded Human prostate by Immunohistochemistry.
• 

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-RUNX2 antibody [1D8] (ab115899)
  ab115899, at 5 µg/ml, staining RUNX2 in formalin fixed, paraffin embedded Human uterus by Immunohistochemistry
• 

  Western blot - Anti-RUNX2 antibody [1D8] (ab115899)
  Anti-RUNX2 antibody [1D8] (ab115899) + SJCRH30 cell lysate
  
  Predicted band size : 57 kDa
  
• 

  Western blot - Anti-RUNX2 antibody [1D8] (ab115899)
  Anti-RUNX2 antibody [1D8] (ab115899) + K562 cell lysate
  
  Predicted band size : 57 kDa
  
• 

  Immunocytochemistry/ Immunofluorescence - Anti-RUNX2 antibody [1D8] (ab115899)
  ab115899, at 10 µg/ml, staining RUNX2 in Hela cells by Immunofluorescence.
• 

  ELISA - Anti-RUNX2 antibody [1D8] (ab115899)
  Detection limit for recombinant, tagged RUNX2 is approximately 0.03 ng/ml as a capture antibody.